Latest HER2/neu Stories
Study Results Highlight Molecular Similarities and Differences between Uterine Papillary and Ovarian Serous Carcinomas, and between Epithelial Ovarian and Endometrial Cancers IRVING,
Phase 1 study of MM-302 will be presented in a plenary oral session CAMBRIDGE, Mass., March 26, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.
RnRMarketResearch.com adds HER-2 Positive Breast Cancer Market in the US 2015-2019 and Global HER-2 Positive Breast Cancer Market 2015-2019 industry research reports in its store. DALLAS, March
TAMPA, Fla., March 12, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc.
Herlev University Hospital selects ONCOtopix™ Dx a truly open quantitative digital pathology solution.
WORCESTER, Mass. and TORONTO, Feb.
NEW YORK, Feb.
Analysis of Phase I Trial indicates Safety and positive immune response data in 21 of 21 patients administered Folate Receptor Alpha Vaccine for breast and ovarian cancers SEATTLE,
-- Novel irreversible pan-erbB inhibitor is active against patient-derived GBM xenografts overexpressing EGFR, including the disease-driving EGFRvIII mutation MENLO PARK, Calif., Dec.
SAN DIEGO, Dec. 12, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
- A handkerchief.
- In general, any miraculous portrait of Christ.